Related Experiment Video
Updated: Jul 19, 2025
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
A Pilot Study of Anlotinib as a Combination Treatment in Advanced Nasopharyngeal Carcinoma
Rui Zhou1, Ping Zhou1, Yi-Feng Yu1
1Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, People's Republic of China.
Aims:
To investigate the short-term objective response and treatment toxicity of anlotinib as a combination treatment in patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (RM-NPC).
Methods:
Patients with RM-NPC who received anlotinib as a combination treatment between March 2021 and July 2022 were retrospectively analyzed.The efficacy and safety of anlotinib as a combination treatment were analyzed.
Results:
A total of 17 patients with RM-NPC were included in this study. Of these patients, 2 (11.8%) had local recurrence, 4 (23.5%) had cervical lymph node recurrence, and 11 (64.9%) had distant failure. The most common metastatic site was the liver (47.1%), followed by the lung (23.5%) and bone (23.5%). Anlotinib was given as first-line treatment in 3 patients (17.6%), second lines treatment in 7 patients (41.2%), and third to six-lines treatment in 7 patients (41.2%). All patients received anlotinib combined with chemotherapy and/or immunotherapy. One patient achieved a complete response (5.9%), 7 patients had a partial response (41.2%), 5 patients had stable disease (29.4%), and 4 patients had progressive disease (23.5%). The overall disease control rate and the overall response rate were 76.5% and 47.1%, respectively. The median progression-free survival was 8.1 months, and the median overall survival was not reached. The incidence of grade 3 adverse events was 30%. No unexpected side effects or treatment-related death were observed.
Conclusion:
Anlotinib, as a combination treatment, has a promising antitumor activity and a manageable safety profile in patients with RM-NPC. Our results add to the growing evidence that supports the benefits of combining antiangiogenic drugs in RM-NPC. Randomized controlled clinical trials investigating the evaluation of anlotinib are warranted.
Insights
Anlotinib combination therapy shows promising anti-tumor effects for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). The treatment demonstrated a 47.1% overall response rate with manageable side effects in this patient group.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) presents significant treatment challenges.
- Effective therapeutic strategies for RM-NPC are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the short-term objective response and treatment toxicity of anlotinib combined with other therapies in patients with RM-NPC.
- To assess the efficacy and safety profile of anlotinib in a real-world clinical setting for RM-NPC.
Main Methods:
- Retrospective analysis of 17 patients with RM-NPC treated with anlotinib combination therapy between March 2021 and July 2022.
- Efficacy endpoints included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
- Safety was assessed by monitoring treatment-related adverse events, including Grade 3 events.
Main Results:
- The overall response rate (ORR) was 47.1% (1 complete response, 7 partial responses), and the disease control rate (DCR) was 76.5%.
- Median progression-free survival (PFS) was 8.1 months; median overall survival (OS) was not reached.
- Grade 3 adverse events occurred in 30% of patients, with no unexpected toxicities or treatment-related deaths reported.
Conclusions:
- Anlotinib combination therapy exhibits promising antitumor activity and a manageable safety profile in patients with RM-NPC.
- These findings support the use of antiangiogenic drugs in combination regimens for RM-NPC.
- Further investigation through randomized controlled trials is warranted to confirm these results.
